BEIJING (Reuters) - China has approved imports of Johnson & Johnson’s Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.
The drug will be used to treat moderate to severe plaque psoriasis in adults who are suitable for systemic therapy, the administration said.
J&J is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the treatment, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.
Reporting by Roxanne Liu in Beijing and Brenda Goh in Shanghai; Editing by Muralikumar Anantharaman
Our Standards: The Thomson Reuters Trust Principles.